SYRACUSE — Syracuse-Wawasee Trail Committee met Monday evening, April 18, and Megan McClellan, executive director, gave the committee an update on several trail projects.

By ANDREA NEAL From the time he was a youngster, Eli Lilly was fascinated by pharmaceuticals. At 16, he served as an apprentice at the Good Samaritan Drugstore in Lafayette. During the day, he stocked shelves, washed bottles and ran errands. At night, he pored over the United States Pharmacopoeia to learn everything he could …read more.

By Andy Ober Assistant Managing Editor, Inside Indiana Business INDIANAPOLIS — Indiana’s life sciences initiative has been awarded a two-year, $2.9 million grant from Lilly Endowment Inc. BioCrossroads says the funding will support its ongoing charitable, educational and scientific efforts. BioCrossroads Chief Executive Officer, David Johnson, says the grant comes at a “pivotal point in …read more.

By GERRY DICK Inside Indiana Business INDIANAPOLIS — Indianapolis-based Eli Lilly and Co. Chief Executive Officer, John Lechleiter, said the drug maker is back in growth mode after a painful period of “building a bridge while we crossed it.” In a speech Friday, Sept. 11, to the Economic Club of Indiana, Lechleiter said Lilly is stronger and …read more.

By ANDY OBER InsideINdianaBusiness INDIANAPOLIS — Indianapolis-based Eli Lilly and Co. says the diabetes treatment Jardiance met its primary endpoint in a latest clinical trial. The company says the treatment lowered cardiovascular risk in adults with type 2 diabetes. Lilly says the long-term trial involved more than 7,000 patients from 42 countries. at high risk …read more.

Turkey Creek Township Trustee Barb Griffith reported Monday on an unwitting snafu by the contracted groundskeeper of Bethel Cemetery. In remediating the condition of the cemetery’s vegetation, the groundskeeper removed two cedar trees in the northeast corner of the cemetery. Griffith heard from three citizens who objected to cutting down the trees and her subsequent …read more.

Eli Lilly and Company announced yesterday that the European Commission granted marketing authorization for Trulicity (dulaglutide) solution for injection. Trulicity, a GLP-1 receptor agonist, is a once-weekly, injectable solution designed to improve glycaemic control in adults with type 2 diabetes. The medicine comes in a ready-to-use pen with a pre-attached, hidden needle. Trulicity received a …read more.

Eli Lilly and Company (NYSE: LLY) today announced that SQUIRE, a recently completed Phase III study, met its primary endpoint, finding that patients with stage IV metastatic squamous non-small cell lung cancer experienced increased overall survival when administered necitumumab in combination with gemcitabine and cisplatin as a first-line treatment, as compared to chemotherapy alone. The …read more.

Eli Lilly and Company (NYSE: LLY) announced today Phase III clinical trial results from enzastaurin’s PRELUDE study, which explored the molecule as a monotherapy in the prevention of relapse in patients with diffuse large B-cell lymphoma (DLBCL). The study failed to show a statistically significant increase compared to a placebo in disease-free survival in patients …read more.

Eli Lilly and Company today announced that it is working closely with Indianapolis on a proposal to invest an additional $180 million in the company’s Indianapolis-based insulin manufacturing operations. The investment is in addition to the company’s November 2012 announcement of a $140 million expansion of the company’s Indianapolis insulin manufacturing operations. Together, the investments …read more.

Eli Lilly and Company today provided an update on the next steps planned for solanezumab, its Phase 3 monoclonal antibody being studied as a potential therapy for patients with mild Alzheimer’s disease. Following discussions with regulators in the U.S., Europe and Canada, Lilly plans to conduct an additional Phase 3 study of solanezumab in patients …read more.

Eli Lilly and Company (NYSE: LLY) presented a record-breaking gift of $12.4 million to the United Way. As the largest gift in the company’s history, the donation represents the contributions of Lilly’s U.S. employees and retirees, plus a matching gift from the Lilly Foundation. Lilly Chairman, President, and Chief Executive Officer John C. Lechleiter, Ph.D., …read more.

Chautauqua-Wawasee presents the first session in its educational series, “From the Ground Up,” this week. These sessions are loosely based on Eli Lilly’s book, “Early Wawasee Days.” Go back in time to learn about the archeological background, Native American history and area pioneer experiences from 10:30 a.m. to noon Saturdays, July 14, 21 and 28 …read more.